Topical drug delivery is critical for treating ocular diseases but suffers from significant defects including low drug availability, long-term frequent administration, and damage to ocular surface, which largely restrict treatment efficacy and influence quality of life. Here, we describe the formation of a durable and protective therapeutic nanocoating on ocular surface by simply instilling biomimetic drug-loaded nanoparticles. Coating with sebocyte membranes that are engineered to overexpress integrin-β1 generates adhesive nanoparticles that can specifically bind to Arg-Gly-Asp sequence on the fibronectin of ocular epithelium. By virtue of the introduction of sebocyte membranes and the associated lipids, coated nanoparticles can supplement the lipid layer and benefit the stability of tear film. After instillation, formed nanocoating consisting of anchored nanoparticles on ocular surface retains up to 24 h during ex vivo human and in vivo mouse studies. Therapeutic values of this approach are demonstrated in mouse and rabbit models of dry eye disease. Nanocoating carrying clinical dexamethasone effectively improves corneal epithelium recovery, decreases corneal opacity and inflammatory cytokine levels, and restores tear secretion. The present study demonstrates an alternative to protect ocular surface and extend topical delivery of various drugs, supporting the potential of therapeutic nanocoating to treat eye diseases.

局部给药是治疗眼部疾病的关键，但存在药物利用率低、长期频繁给药、眼表损伤等显着缺陷，在很大程度上限制了治疗效果并影响生活质量。在这里，我们描述了通过简单地滴注仿生药物纳米颗粒在眼表上形成耐用和保护性的治疗性纳米涂层。用被设计为过表达整合素-β1 的皮脂细胞膜涂层产生粘性纳米颗粒，该纳米颗粒可以特异性结合眼上皮纤连蛋白上的 Arg-Gly-Asp 序列。由于皮脂细胞膜和相关脂质的引入，涂层纳米颗粒可以补充脂质层并有利于泪膜的稳定性。滴注后，在离体人类和体内小鼠研究期间，由眼表面锚定的纳米颗粒组成的纳米涂层可保留长达 24 小时。这种方法的治疗价值在干眼病的小鼠和兔模型中得到了证明。携带临床地塞米松的纳米涂层有效改善角膜上皮恢复，降低角膜混浊和炎性细胞因子水平，恢复泪液分泌。本研究展示了一种保护眼表和延长各种药物局部给药的替代方法，支持治疗性纳米涂层治疗眼部疾病的潜力。携带临床地塞米松的纳米涂层有效改善角膜上皮恢复，降低角膜混浊和炎性细胞因子水平，恢复泪液分泌。本研究展示了一种保护眼表和延长各种药物局部给药的替代方法，支持治疗性纳米涂层治疗眼部疾病的潜力。携带临床地塞米松的纳米涂层有效改善角膜上皮恢复，降低角膜混浊和炎性细胞因子水平，恢复泪液分泌。本研究展示了一种保护眼表和延长各种药物局部给药的替代方法，支持治疗性纳米涂层治疗眼部疾病的潜力。